GSK Says China Revenues Recovered in Q4

GlaxoSmithKline said that its China revenues turned higher in the fourth quarter of 2013, after sales dropped a disastrous 61% in Q3. Specific numbers were not disclosed. The story of GSK’s bribery scandal broke right at the beginning of Q3, and company officials had said earlier its sales were beginning to improve in September, at the end of the quarter. Back then, the small bit of good news seemed hopelessly optimistic; it may have been accurate. More details.... Stock Symbol: (NYSE: GSK) Share this with colleagues: // //